Section Arrow
Quote
ORGO.NASDAQ
- Organogenesis Holdings
Quotes are at least 15-min delayed:2025/07/04 10:28 EDT
Last
 4.25
+0.2 (+4.94%)
Day High 
4.25 
Prev. Close
4.05 
1-M High
4.085 
Volume 
494.56K 
Bid
4.05
Ask
4.5
Day Low
4.01 
Open
4.08 
1-M Low
2.6101 
Market Cap 
513.76M 
Currency USD 
P/E 60.5 
%Yield -- 
10-SMA 3.56 
20-SMA 3.36 
50-SMA 3.63 
52-W High 6.71 
52-W Low 2.28 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.16/0.22
Enterprise Value
547.96M
Balance Sheet
Book Value Per Share
1.91
Cash Flow
Cash Flow Yield
0.01
Income Statement
Total Revenue
482.04M
Operating Revenue Per Share
3.61
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
TLRYTilray Brands0.5387+0.0535+11.03%-- 
RGCRegencell Bioscience Holdings Limited22.99+12.63+121.91%-- 
CGCCanopy Growth Corp1.28+0.09+7.56%-- 
IXHLIncannex Healthcare0.2094+0.0025+1.21%-- 
HLNHaleon plc10.25-0.01-0.10%23.95PE
Quotes are at least 15-min delayed：2025/07/04 10:28 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.